ClinicalTrials.gg
CompletedNCT07945587Updated Nov 18, 2026

Prediction of Fluid Responsiveness Using the PEEP Test in Patients With Sepsis

An interventional study of End-Expiratory Occlusion Test (EEOT) and PEEP Test in Sepsis, sponsored by Bakirkoy Dr. Sadi Konuk Research and Training Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Bakirkoy Dr. Sadi Konuk Research and Training Hospital · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 2 years 6 months after the study started (first participant enrolled Mar 2024, registered Oct 2026).
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 74 studies in Sepsis with a site in Turkey — 15 open to participants now, 17 under way, none of them phase 3. Sepsis · Turkey.

Enrollment
21st of 24
60 · median 119
Started
2024
with 7 others
No phase
12 of 74
2 open now
Registered
74th of 74
by date
Lead sponsor
2 of 74
Bakirkoy Dr. Sadi Konuk Research and Training Hospital

Among the 74 studies in Sepsis with a site in Turkey, this one is the 21st largest by enrollment of the 24 interventional ones that give a count, is one of 8 that started in 2024, is one of 12 with no phase, and was the 74th registered.

Sepsis

2,421 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

15 of the 74 studies in Sepsis with a site in Turkey are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 321 Sepsis studies recruiting now, 213 (66%) set no upper age limit and 53 (17%) stop at 75 or younger; 68 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies in Sepsis with a site in Turkey, or all of them as a file.
02

Study summary

Fluid resuscitation is a cornerstone of sepsis management. However, to avoid unnecessary fluid loading, it is important to assess fluid responsiveness, ideally without administering additional fluids. The PEEP test may offer a means of predicting fluid responsiveness by inducing a transient increase in cardiac preload through a temporary reduction in intrathoracic pressure, without requiring a fluid bolus.

This study evaluated whether the positive end-expiratory pressure (PEEP) test could predict fluid responsiveness in mechanically ventilated patients with sepsis.

In this prospective, single-center study, 60 mechanically ventilated patients with sepsis were enrolled when their treating clinicians had independently planned a fluid challenge. Before the fluid challenge, patients underwent an end-expiratory occlusion test (EEOT) followed by a PEEP test. During the PEEP test, PEEP was temporarily reduced from a baseline level of ≥10 cmH2O to 5 cmH2O for one minute, and changes in cardiac index (CI) were recorded. Fluid responsiveness was defined as an increase in CI of at least 10% following a 300 mL crystalloid fluid challenge.

The primary objective was to evaluate the diagnostic accuracy of the PEEP test for predicting fluid responsiveness. Additional analyses evaluated the diagnostic accuracy of the PEEP test in subgroups defined by baseline respiratory system compliance (Crs) and driving pressure (DP), and examined the relationships between PEEP test-induced changes in Crs and DP and the corresponding change in CI.

Read the detailed description

This prospective, single-center physiological diagnostic accuracy study was conducted in the Anesthesiology and Reanimation Intensive Care Unit of Bakirkoy Dr. Sadi Konuk Research and Training Hospital, Istanbul, Türkiye, between March 26, 2024, and March 17, 2025.

The study investigated whether a temporary reduction in positive end-expiratory pressure (PEEP) could predict fluid responsiveness in mechanically ventilated patients with sepsis. By transiently reducing intrathoracic pressure and potentially increasing venous return and cardiac preload, the PEEP test may provide a means of assessing fluid responsiveness without administering additional fluids solely for diagnostic testing.

The study included patients with sepsis for whom an intravenous fluid challenge (FC) had been planned by the treating clinician as part of routine clinical care and who met the eligibility criteria, including invasive mechanical ventilation in volume-controlled ventilation (VCV) mode, baseline PEEP ≥10 cmH₂O, and cardiac index (CI) monitoring using pulse contour analysis. The decision to administer fluids was made independently by the treating clinician and was not determined by the study protocol.

Before the fluid challenge, all enrolled participants underwent an end-expiratory occlusion test (EEOT) followed by a PEEP test as study-specific physiological assessments. The EEOT consisted of a 30-second end-expiratory hold maneuver. During the PEEP test, PEEP was temporarily reduced from its baseline level (≥10 cmH2O) to 5 cmH2O for one minute and subsequently restored to baseline. Changes in CI, other hemodynamic parameters, and respiratory mechanics were recorded during the testing sequence.

Following the physiological assessments and hemodynamic stabilization, the fluid challenge previously planned by the treating clinician was administered as a 300 mL intravenous crystalloid bolus over 15 minutes via a central venous catheter. Fluid responsiveness was defined as an increase in CI of ≥10% following the fluid challenge.

The primary analysis evaluated the diagnostic accuracy of the percentage change in CI during the PEEP test for predicting fluid responsiveness using receiver operating characteristic (ROC) curve analysis and the area under the ROC curve (AUROC).

Additional analyses evaluated the diagnostic accuracy of the PEEP test in subgroups defined by baseline respiratory system compliance (Crs) and driving pressure (DP). Changes in Crs (ΔCrs) and DP (ΔDP) during the PEEP test and their correlations with the percentage change in CI (%ΔCI) were investigated. Changes in other hemodynamic parameters, including heart rate, mean arterial pressure, central venous pressure, stroke volume index, stroke volume variation, pulse pressure variation, and systemic vascular resistance index, were also evaluated during the PEEP test.

A total of 60 patients were included in the study.

03

Conditions studied

  • Sepsis

Browse trials for

Keywords

  • Fluid responsiveness
  • PEEP test
  • Positive end-expiratory pressure
  • Cardiac index
  • Respiratory system compliance
  • Driving pressure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.
  • Diagnosis of sepsis with a fluid challenge planned by the treating clinician.
  • Invasive mechanical ventilation in volume-controlled mode with a tidal volume of 7-8 mL/kg predicted body weight and no spontaneous respiratory effort.
  • Baseline PEEP ≥10 cmH₂O and plateau pressure ≤30 cmH₂O.
  • Baseline respiratory system compliance (Crs) ≥30 mL/cmH₂O.
  • Minimally invasive hemodynamic monitoring using pulse contour analysis for cardiac output measurement.

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years.
  • Unavailability of pulse contour analysis-based cardiac output monitoring.
  • Cardiac arrhythmias, including atrial fibrillation.
  • Absence of a central venous catheter or catheter placement in the femoral vein.
  • Prone positioning.
  • PEEP \<10 cmH₂O.
  • Respiratory system compliance(Crs) \<30 mL/cmH₂O.
  • Extracorporeal membrane oxygenation (ECMO).
  • Presence of a chest tube or pleural drainage catheter.
  • Pregnancy.
  • Known right ventricular failure.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Physiological Testing Group

    All enrolled participants underwent an end-expiratory occlusion test followed by a PEEP test before a clinically planned fluid challenge.

    Diagnostic Test: End-Expiratory Occlusion Test (EEOT) · Diagnostic Test: PEEP Test

Interventions

  • Diagnostic testEnd-Expiratory Occlusion Test (EEOT)

    An end-expiratory occlusion test (EEOT) was performed using a 30-second end-expiratory hold maneuver in mechanically ventilated patients before the PEEP test. The maximum cardiac index (CI) reached during the maneuver and associated hemodynamic parameters were recorded.

  • Diagnostic testPEEP Test

    The PEEP test was performed in patients receiving invasive mechanical ventilation in volume-controlled ventilation (VCV) mode. PEEP was temporarily reduced from its baseline level (≥10 cmH₂O) to 5 cmH₂O for one minute. The change in cardiac index (ΔCI) during the maneuver was assessed, while other hemodynamic and respiratory parameters, including respiratory system compliance (Crs) and driving pressure (DP), were also recorded. PEEP was then restored to its baseline level.

06

What researchers measure

Primary outcomes

  1. Diagnostic Accuracy of the PEEP Test for Predicting Fluid Responsiveness

    The diagnostic accuracy of the PEEP test was evaluated using the percentage change in cardiac index (ΔCI, %) during PEEP reduction, calculated from baseline CI and the maximum CI recorded during the 1-minute test. Fluid responsiveness was defined as an increase in CI of ≥10% following a 300 mL crystalloid fluid challenge. Diagnostic performance was assessed using receiver operating characteristic (ROC) curve analysis and reported as the area under the ROC curve (AUROC).

    Time frame: At baseline (immediately before the PEEP test), during the 1-minute PEEP test, and immediately upon completion of the subsequent 15-minute fluid challenge.

Secondary outcomes

  1. Change in Stroke Volume Index (SVI) During the PEEP Test

    The change in stroke volume index (SVI) was calculated as the difference between the SVI value recorded at the time of maximum cardiac index (CI) during the 1-minute PEEP test and the baseline SVI value. Changes were expressed in mL/m².

    Time frame: At baseline (immediately before the PEEP test) and at the time of maximum cardiac index (CI) during the 1-minute PEEP test.

  2. Change in Pulse Pressure Variation (PPV) During the PEEP Test

    The change in pulse pressure variation (PPV) was calculated as the difference between the PPV value recorded at the time of maximum cardiac index (CI) during the 1-minute PEEP test and the baseline PPV value. Changes were expressed in percentage points.

    Time frame: At baseline (immediately before the PEEP test) and at the time of maximum cardiac index (CI) during the 1-minute PEEP test.

  3. Correlation Between Changes in Respiratory System Compliance (Crs) and Percentage Change in Cardiac Index (CI) During the PEEP Test

    Changes in respiratory system compliance (ΔCrs), expressed in mL/cmH₂O, were calculated from baseline to the 1-minute PEEP test. The association between ΔCrs and the percentage change in cardiac index (ΔCI, %) during the PEEP test was assessed using Spearman correlation analysis. The correlation coefficient (r) was reported.

    Time frame: At baseline (immediately before the PEEP test) and during the 1-minute PEEP test.

  4. Correlation Between Changes in Driving Pressure (DP) and Percentage Change in Cardiac Index (CI) During the PEEP Test

    Changes in driving pressure (ΔDP), expressed in cmH₂O, were calculated from baseline to the 1-minute PEEP test. The association between ΔDP and the percentage change in cardiac index (ΔCI, %) during the PEEP test was assessed using Spearman correlation analysis. The correlation coefficient (r) was reported.

    Time frame: At baseline (immediately before the PEEP test) and during the 1-minute PEEP test.

  5. Diagnostic Accuracy of the PEEP Test According to Baseline Respiratory System Compliance (Crs)

    The diagnostic accuracy of the PEEP test for predicting fluid responsiveness was evaluated across subgroups stratified according to baseline respiratory system compliance (Crs). The subgroup cutoff was determined based on the distribution of baseline Crs values in the study population. Diagnostic performance was assessed using the area under the receiver operating characteristic curve (AUROC).

    Time frame: At baseline (for respiratory system compliance assessment), during the 1-minute PEEP test, and immediately upon completion of the subsequent 15-minute fluid challenge.

07

Study locations

1 site
  • Bakirkoy Dr. Sadi Konuk Training and Research Hospital
    Istanbul, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Mar 2025, 11 months.

Of 302 non-industry interventional studies with no phase under Sepsis, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's 11 months is below that.

Counting every sponsor, half of 325 studies reached it within 22 months; a quarter within 11 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2026
First posted
Nov 18, 2026
StartActual
Mar 26, 2024
Primary completionActual
Mar 17, 2025
CompletionActual
Mar 17, 2025
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945587
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Mar 26, 2024
Primary completion
Mar 17, 2025
Completion
Mar 17, 2025
Last update
Nov 18, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion